A carregar...

Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma

Pembrolizumab is an effective therapy in patients with metastatic melanoma. However, not all patients derive benefit. It is postulated that an increase in regulatory T cells in melanoma patients can impair the response to immunotherapies. Continuous low dose temozolomide has shown to cause immunomod...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Melanoma Res
Main Authors: Swami, Umang, Monga, Varun, Freesmeier, Michele, Zhang, Weizhou, Bossler, Aaron D., Zakharia, Yousef, Milhem, Mohammed
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717692/
https://ncbi.nlm.nih.gov/pubmed/30829928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000592
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!